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Abstract
Background: Chemokine ligands (CCLs) play a pivotal role in tissue injury before and after kidney transplantation.
Meanwhile, transplantation improves patient’s survival and diminishes morbidity. It is hypothesized, then, that kidney
transplantation diminishes pre-transplant (pre-TX) levels of circulating inflammatory CCLs. This retrospective study
compared circulating levels and profiles of CCLs before transplantation (pre-TX) and after transplantation (post-TX).
Methods: Nineteen CCLs (1, 2, 3, 4, 5, 8, 11, 13, 15, 17, 21, 24, 26, 27, CXCL 5, 8, 10, 12 and 13) were measured in
47 stable post-TX recipients, and their stored pre-TX plasma was analyzed by multiplexed fluorescent bead-based
immunoassay. Twenty normal controls were included for comparisons. Normalized data was presented as mean ± SD
and non-normalized data as median (5–95 % CI). Significance was measured at p < 0.01. Arbitrary upper and
lower margins for each CCL at the 95 % CI or 2SD levels in each group were chosen to calculate the percentile
of patients in the other group who exceeded these limits. Significant CCL levels present in more than 75 % of
patients in a group that exceeded the arbitrary upper or lower set margins in the other two groups were labeled
as preferentially characteristic for the respective group.
Results: More than 75 % of pre- and post-TX patients had levels that exceeded the upper control for CCL1, 11, 15 and
CCL15, CCL26 and CXCL13 levels, respectively. More than 75 % of pre- and post-TX patients exceeded the lower
control for CCL3, 21, and CCL5 limits, respectively. More than 75 % of post-TX patients demonstrated elevated
levels of CCL2, 3, 21, 26 and CXCL13 above the upper pre-TX cut offs. Meanwhile, more than 75 % of post-TX
patients exceeded the lower pre-TX levels for CCL1, 4, 5, 8, 13, 15, 17, 24 and CXCL8 and10. Pre-TX was
preferentially characterized by elevated CCL1 and 15 and diminished CCL3 and 21. Post-TX was preferentially
characterized by elevated CCL26 and CXCL13 and diminished CCL4 and 5.
Conclusion: End stage kidney disease is associated with enhanced circulating inflammatory chemokine levels. Stable
kidney transplantation is associated with 1) lowered burden of circulating inflammatory chemokine levels and, 2)
elevation in the pro T-helper2 chemokine, CCL26 and the homeostatic CXCL13.
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Background
Chemokines are small proinflammatory proteins that act
as both chemoattractants and activators of leukocytes
[1]. Chemokines are considered as a subset of the cyto-
kine family responsible for cell migration, activation
and tissue injury [2]. At least 50 structurally related
chemokines have been discovered thus far, and they can
be categorized into four subfamilies. An additional 20
receptors have been identified. On binding to their cell
receptors, chemokine C-C motif ligands signal leukocyte
recruitment and activation leading to tissue inflammation
[3]. Extensive literature has delineated the pivotal role
of CCLs in dialysis patients [4], vascular injury [5, 6]
and transplant pathology [7].
Most chemokines share multiple cell receptors and have
promiscuous functions ensuring robust inflammatory
responses [1]. In general terms, however, the chemokines
C-X-C motif ligand (CXCL) predominantly associates with
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neutrophil recruitment and activation [8], whereas the
chemokines C-C motif ligand (CCL) is targeted more to
lymphocyte and macrophage activation [8]. It is widely
recognized that CCL14, 19, 20, 21, 25, 27, as well as
CXCL12 and 13 have homeostatic functions [8], while typ-
ically CCL2, 3, 4, 5, 11, CXCL1, 2, 8, and 10 play a proin-
flammatory role [8]. Many inflammatory diseases and
animal models demonstrate certain chemokine profiles
with attracting T helper (Th) 1 or Th2 immunopathology.
Th1 is typically associated with interferon (IFN) gamma,
CCL1, 2, 8, 11, CCL3, CCL4, CCL5 and CXCL10 [9, 10]
while Th2 is associated with IL4, IL5, IL13 and CCL3 [11].
The Th1 response is associated with a delayed type of
hypersensitivity and cellular rejection [12], while Th2 is
associated with humoral responses and tissue fibrosis
[12]. Since certain chemokines are known to associate
with certain biological functions, disruption of a par-
ticular chemokine activation cascade has been used as a
promising tool to identify putative targets to treat
human diseases [13–15]. A plethora of potential thera-
peutic agents exist that can block chemokine receptors
and disrupt chemokine functions [16, 17]. It is a matter
of time before the use of these agents in routine clinical
practice will be achieved.
Hemodialysis patients awaiting transplantation have a
high risk of mortality and morbidity. This is largely due
to the presence of cardiovascular disease in which che-
mokines play a critical role [18]. After a successful renal
transplant, the patient’s risk of having a cardiovascular
events diminishes, but remains elevated compared to
the general population. This is in part due to enhanced
circulating chemokine ligand levels [19].
Therefore, studying chemokine biological functions
before and after renal transplantation may assist in
defining the magnitude of inflammatory burden caused
by differentially elevated chemokine levels, and help to
identify putative chemokines of potential future thera-
peutic importance in this population.
With this in mind, we aimed this study to compare the
circulating chemokine profiles before and after kidney
transplantation. We were interested in determining which
circulating chemokine best distinguishes the impact of
transplantation. We also sought to identify the chemokine
which best correlates with the stable hemodialysis state in
patients waiting for a transplant, as well as and the impact
of transplantation thereof.
Methods
The protocol was approved by the Regional Ethics Board
at the University of Saskatchewan (Bio #11-220). Forty-
seven patients were identified during the post-transplant
period as eligible for the study based on the following
inclusion criteria: had been stable on hemodialysis for at
least 6 months, and had stored plasma immediately prior
to transplant surgery at -80 °C. All renal transplant re-
cipients (RTR) were adults older than18 years old and
were followed in one out-patient university clinic. The
following subjects were excluded from participation:
those requiring hospitalization or have a change of more
than 10 % in serum creatinine in the previous 3 months,
treatment for any acute illness, apparent infection on
the study visit and those who have a biopsy proven BK
viral nephropathy. Written consent was taken from par-
ticipants and plasma samples were collected for analysis
of a large number of inflammatory chemokines includ-
ing chemokine ligands. Patient demographics (age, sex,
race), cause of kidney failure, mode of dialysis prior to
transplant were collected. The estimated glomerular
filtration rate (eGFR) was calculated from the following
equation: GFR (CKD-EPI) =141X min(Scr/k,1)α X
max(Scr/k,1)-1.209 X.993Age X1.018 [if female] X (1.159
[if black] where k = 0.7 if female, k = 0.9 if male, α = -0.329
if female, α = -0.411 if male, min = minimum of Scr/k
or 1 and max = maximum Scr/k or 1, Scr = serum
creatinine (mg/dL).
Blood was collected from healthy controls. Volunteers
were excluded if they were smokers, were under treat-
ment for any acute illness or had infection, hypertension,
cancer, pregnancy, diabetes, or had experienced previous
cardiovascular (CV) events. Mean age was 41 ± 14.1 years
old and 60 % were females.
Multiplexed fluorescent bead-based immunoassay
Plasma from 47 RTR and 20 normal controls was frozen
at -80 °C until time of immunoassay (Luminex) meas-
urement. The nineteen CCLs measured in this study
were part of two luminex kits (Milliplex Map Human
Cytokine/Chemokine Panel II 23-plex, EMD Millipore,
Billerica, MA, USA and Bio-Plex Pro Human Cytokine
27-plex, Bio-Rad Laboratories Canada Ltd, Mississauga,
Ontario, Canada). Assays were performed as per manu-
facturer instructions. Briefly, samples were centrifuged
to remove the fat and particles, and added to the plate
with the bead mixture. Incubation occurred for 30 min,
and then washing was performed three times. Biotin-
coupled antibody cocktail was added to each well, and
the plate was incubated for 30 min followed by washing.
Streptavidin conjugated phycoerythrin was added to the
plate and incubated for 15 min in dark room. Finally
assay buffer was added after washing, and the analysis
was carried out on the Bio-Plex 200 instrument. The data
was analyzed by Bio-Plex Manager Software (version 6.1).
Concentrations obtained by the standard curve were
expressed in pictograms per milliliters [20, 21]. Levels
below the detection levels reported by the company,
particularly in normal controls were assigned the lowest
detection limit to enable us to perform the statistical
comparisons.
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Statistics
SPSS version 22® (IBM Corp., Armonk, NY, USA) was
used for the data collection and analysis. Data were cal-
culated and presented as the mean ± standard deviation
(SD) for normalized data and median (CI 95–5 %) for
non-normalized data. All of the hypotheses tested were
2-tailed and a p value < 0.01 was considered statistically
significant. Group differences were analyzed by Student
t test and Mann Whitney for normally distributed, non-
normally distributed variables, respectively.
Normality was assessed by Shapiro-Wilk test (because
the data was less than 2000). Comparisons between che-
mokine ligand levels were performed between pre-TX
and post-TX patients groups and between each patient
group and control. Comparison results were presented
in two ways. First, we presented the percentile of pre-
and post-TX patients who had chemokine levels above
or below an arbitrary defined upper and lower control
CCL levels. For the sake of this study we set the lower
control set point at the 5 % CI or 2SD below the median
or mean control levels, respectively. Similarly, the upper
control level was set to be at least 95 % CI or 2 SD
above the median or mean control CCL level, respect-
ively. The same method was used to calculate the per-
centile of post-TX patients with CCL levels above or
below the pre-TX predefined levels.
Results
Table 1 shows patient’s demographics. Forty-seven out
of 65 patient participants were deemed stable and
participated in the study. The most common reason for
exclusion of the 18 other potential participants was that
the patient was not scheduled for routine blood work on
the same day of the clinic appointment, followed by the
presence of flu-like symptoms or urinary tract infections.
The average pre-transplant age was 42.7 years, and the
average time post-transplant was 6.51 ± 2.03 years. The
mean duration between the Pre-TX and Post-TX- test
points was 9.82 (9.82–10.14) years. Approximately half
(51.1 %) of the RTR were male. Most patients were on
triple immunosuppressive drug therapy, with a myco-
phenolic acid derivative, a calcineurin inhibitor, and
prednisone, and all patients were on hemodialysis prior
to the transplant.
A) Comparison between pre-TX CCL and control levels
Results are presented in Table 2(a-b). Out of the 19
CCL measures, CXCL5, 8, 12 and 13 were similar
to control levels. Nine CCLs (CCL1, 8, 11, 13, 15,
17, 24, 27, CXCL10) were significantly elevated and
five CCLs (CCL2, 3, 5, 21, 26) were significantly
lower than the control values.
B) Comparison between post-TX CCL and control levels
As presented in Table 2(a-b), seven chemokines
had normal levels. They were: CCL8, 11, 13, 17, 21,
CXCL 10 and 12. Only four markers (CCL15, 26,
27 and CXCL 13) were significantly elevated and
the remaining eight markers (CCL1, 2, 3, 4, 5, 24,
CXCL5, 8) were significantly lower than the
control values.
Table 1 Patient demographics
Parameter Pre-TX Post-TX P value
Number 47 47
Male (n) % (24/47) 51.1 %
Female (n) % (23/47) 48.9 %
Patient age 42.73 ± 14.71 49.11 ± 14.53 0.049
Patient age ≥ 60 (yrs) (n) % 12.80 % 25.30 %
Ethnic origin
Caucasian 72.34 %
First Nation or Metis 25.53 %
Asian 2.13 %
Diabetic nephropathy 29.78 %
Type of TX (LD/DD) 13/34
Hemodialysis duration (yrs) 3.01 (1.72–4.13) ─
Duration transplant (yrs) ─ 6.51 ± 2.03
Duration between first and second test (yrs) 9.82 (9.82–10.14)
GFR (CKD-EPI) ─ 52.1 (38.6–61.3)
GFR (CKD-EPI) ≥ 60 (n %) ─ 37.5 %
The results are presented as mean ± SD for normally distributed data and median (confidence intervals 5–95 %) for non-normality distributed variables
LD living donor, DD deceased donor
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Table 2 Comparison of circulating levels of inflammatory chemokine ligands in patient and control groups
a
Chemokine (pg/m) Control (n = 20) Pre-transplant Post-Transplant
CCL1 (47/44) 2.9 (2.0–3.8) 7.7 (5.4–9.1) 2.0 (2.0–2.4)
CCL2 (47/45) 231.0 ± 77.9 55.3 (38.9–74.4) 108.1 (98.3–144.5)
CCL3 (46/44) 7.8 (5.3–9.0) 2.1 (1.8–2.5) 4.2 (3.7–4.7)
CCL4 (46/44) 118.3 (96.2–127.2) 149.9 (128–177.8) 47.0 (34.1–80.7)
CCL5 (46/41) 23805.2 ± 4535.9 12399.7 (8403.6–14469) 3312.5 (2474.2–5636.2)
CCL8 (47/44) 27.8 ± 13.6 49.9 (41.4–56.7) 25.8 ± 1 0.6
CCL11 (47/44) 39.0 (14.9–88.1) 192.4 (156.9–236.5) 80.8 (39.2–130.6)
CCL13 (46/42) 44.0 ± 14.4 123.3 (100.2–148.5) 37.6 (20.1–57.5)
CCL15 (47/40) 1292.0 (803.5–1453.7) 7192.7 (5758.8–9180.9) 3233.5 (2233.1–4466.5)
CCL17 (46/43) 34.4 (25.0–52.4) 111.3 (65.2–162) 20.9 (16.1–32.3)
CCL21 (46/44) 290.8 ± 80.3 37.9 (9.7–76.3) 183.7 (159.2–262.3)
CCL24 (47/43) 494.7 (282.8–720.4) 836.1 (667.4–1396.1) 304.9 (223.1–420.9)
CCL26 (47/44) 16.7 ± 10.1 3.7 (3.1–4.6) 48.8 (48.8–48.8)
CCL27 (47/43) 424.9 ± 161.3 1328 (1038.7–1546.9) 816.9 ± 338.7
CXCL5 (46/41) 511.4 (455.9–688.0) 339.7 (243.2–410.4) 337.9 (222.2–443.3)
CXCL8 (47/41) 28.3 ± 8.7 25.7 (21.6–31.9) 11.4 (8.1–13.4)
CXCL10 (46/44) 1183.0 ± 503.1 1868.8 (1601.6–2537.1) 726.8 (542.5–942.8)
CXCL12 (47/44) 2424.7 (2011.8–2816.5) 1987.7 (1567.1–2255.8) 2220.8 (1400.6–2687.5)




Δ change % change P1 P2 P3
CCL1 (47/44) -4.7 (-6.8 - -3.4) -68.6 % 0.000 0.010 0.000
CCL2 (47/45) 64.1 (47.8–86.6) 113.9 % 0.000 0.000 0.000
CCL3 (46/44) 2.1 (0.8–2.6) 90.8 % 0.000 0.000 0.000
CCL4 (46/44) -98.2 (-122.9 - -67.2) -70.5 % 0.010 0.000 0.000
CCL5 (46/41) -814.7 ± 9480.3 -75.6 % 0.000 0.000 0.000
CCL8 (47/44) -23.7 (-29.6 - -15.8) -47.9 % 0.000 0.720 0.000
CCL11 (47/44) -97.4 (-164.4 - -61.59) -59.8 % 0.000 0.080 0.000
CCL13 (46/42) -72.2 ± 77.1 -63.5 % 0.000 0.720 0.000
CCL15 (47/40) -3459.1 (-4848.2 - -1000.7) -50.6 % 0.000 0.000 0.000
CCL17 (46/43) -89.7 (-119.1 - -50.1) -77.6 % 0.000 0.020 0.000
CCL21 (46/44) 157.6 (65.1-208.2) 404.0 % 0.000 0.120 0.000
CCL24 (47/43) -660.1 (-830.3–535.5) -71.0 % 0.000 0.010 0.000
CCL26 (47/44) 44.4 (42.8–45.8) 1096.0 % 0.000 0.000 0.000
CCL27 (47/43) -575.7 (-844.3 - -238.7) -40.3 % 0.000 0.000 0.000
CXCL5 (46/41) -49.1 (-218.3–41.0) -18.8 % 0.030 0.010 0.690
CXCL8 (47/41) -10.8 (-22.7 - -7.8) -54.9 % 0.720 0.000 0.000
CXCL10 (46/44) -1015.3 (-1423.6 - -731.4) -64.2 % 0.000 0.040 0.000
CXCL12 (47/44) 133.3 (-571.7–855.5) 4.9 % 0.050 0.210 0.630
CXCL13 (46/44) 34.1 (16.8–46.1) 213.5 % 0.080 0.000 0.000
For both tables a and b, the results are presented as mean ± SD for normally-distributed, and median (5–95 %) confidence intervals for non-normality distributed
data, respectively. Sample size for patients in the pre-TX/post-TX groups are presented between brackets in column 1. Sample size for the control was n = 20 for
all chemokines
Delta change is calculated from: (post-TX chemokine level—pre-TX chemokine level). Percentage change in inflammatory chemokines level is calculated from:
(post-TX chemokine level—pre-TX chemokine level))/pre-TX chemokine level. P1 represents the p-value between control and pre-TX; P2 represents the p-value
between control and post-TX; P3 represents the p-value between pre-TX and post-TX. P-value computed by Mann-Whitney u – test
Elmoselhi et al. Journal of Inflammation  (2016) 13:32 Page 4 of 9
C) Similarities and dissimilarities between CCL levels
in both patient’s groups (pre- and post-TX)
compared to controls
Both of the pre- and post-TX patients shared some
similarities when compared to the control group. In
particular, CCL2, 3, 4 and 5 were significantly lower
in both groups when compared to control CCL
levels. Both patients’ groups had CCL levels above
the control group for CCL 15 and CCL 27 only.
After transplantation, four pre-TX CCL (CCL 8, 11,
13 and CXCL10) levels were elevated above control
values and were normalized after transplantation.
Similarly, two significantly diminished Pre-TX CCL
levels (CCL17 and 21) saw normalization after
transplantation.
On the other hand, CXCL13 was the only
chemokine that had normal level before
transplantation and saw a significant increase
post-transplantation. Of note, CCL 26 was the
only marker that was significantly diminished
before transplantation and saw a significant
elevation after transplantation. Pre transplant
CCL1, 2 and 24 levels were significantly elevated
above control levels and were decreased after
transplantation to reach a significantly lower
level when compared to control values. On the
other hand, significantly diminished pre-TX CCL
17 and 21 levels were normalized in the post-TX
group.
D)Comparison between pre- and post-TX CCL levels
CXCL5 and 12 had similar levels before and after
transplant, while thirteen markers (CCL1, 4, 5, 8,
11, 13, 15, 17, 24, 27 and CXCL5, 8, 10) saw a
significant decrease, and only five markers
(CCL2, 3, 21, 26 and CXCL13) increased after
transplantation. Table 2 shows also the delta (Δ)
changes in CCL levels after transplantation.
Maximum delta changes were seen CCL15 and
CXCL10.
E) Percentiles of pre- and post- TX patients with
chemokine levels exceeding the control 95 % CI levels
More than 75 % of pre-TX patients had levels below
the lower cut off for CCL3, 21 and levels above the
set upper level for CCL1, 11, 15. After transplant-
ation more than 75 % had lower levels for CCL3, 4,
5 and higher levels for CCL15, 26 and CXCL13. The
cumulative percent of pre- and post-TX patients
with chemokine levels below the set lower control
limit was 13 % (2.1–66 %) and 35.3 ± 29.6 %, respect-
ively. The percent of pre- and post-TX patients with
levels above the 95 % CI control values were 23.9 %
(4.3–69.6 %) and 11.4 % (4.5–34.1 %), respectively.
More information can be viewed in the Additional
file 1: Table S1.
F) Percentiles of post-TX patients with chemokine
levels exceeding the pre-TX 95 % CI levels
More than 75 % of post -TX patients had lower
levels for CCL1, 4, 5, 8, 13, 15, 17, 24, CXCL 8 and
10, compared to the pre-TX. Meanwhile, over 75 %
of patients had levels above the upper pre-TX levels
for CCL2, 3, 21, 26 and CXCL13. The cumulative
percent of post-TX patients with chemokine levels
below the set lower pre-TX limit was 81.8 %
(4.5–92.7 %). The percent of post-TX patients with
levels above the 95 % CI control values were 7.3 %
(2.4–98.1 %). For more information see Additional
file 1: Table S2.
Circulating chemokine profiles preferentially characteristic
for patients before and after TX
Pre-TX CCLs level that showed significance and exceeded,
as well, the upper cut off levels in post-TX and control
values in at least 75 % of patients were CCL1 and 15.
CCLs in the same group that exceeded the lower cut-offs
in the other two groups in >75 % of pre-TX patients were
CCL3 and 21. Likewise the post-TX CCLs that exceeded
both the pre-TX and control levels in over 75 % of post-
TX patients were CCL26 and CXCL13 while CCL 4 and 5
were diminished in more than 75 % of post-TX patients
below the control and pre-TX cut off levels.
Discussion
The results raise several points for discussion. In general,
statistical analysis may not reflect robust biological dif-
ferences. In addition, chemokine levels vary significantly
even among normal people [22]. To strengthen the bio-
logical significance of our results we opted to define ar-
bitrary stringent CCL cut-off levels in the comparative
analyses, in addition to the conventional statistical
methods. We enumerated the number of patients who
had levels beyond the 95 % CI and calculated the per-
centage of patients exceeding these limits. We also set
the P value at <0.01 to perhaps strengthen our conclu-
sions. Secondly, the literature is replete of information
on the inflammatory and homeostatic nature of chemo-
kines in health and disease [23]. We will first comment
on CCL profiles before and after transplant and then
focus on CCLs that preferentially associate with patients
before and after transplantation.
The results of the pre-TX CCL levels raise several
points. Among the 19 CCL chemokines tested, only
CXCL8 which plays a role in neutrophil trafficking [24]
and CXCL13 which is significant in B and T cell traffick-
ing in lymphoid tissues, were within the normal range.
Typically, CXCL8 has an inflammatory function [25] and
CXCL13 has a homeostatic function [26]. Of interest, in
the conventional non-parametric analysis, the proinflam-
matory CCL1, 4, 8, 11, 13, 15, 24, CXCL10 and the
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homeostatic CCL27 [8] were significantly elevated above
controls. Remarkably, more than 75 % in this group had
CCL1, 11, and 15 levels exceeding the upper control set
limits. Chemokines that qualified to be preferentially
characteristic to pre-TX were CCL1 and 15. That is be-
cause their levels were significantly higher than the other
two groups and more than 75 % of the pre-TX patients
demonstrated levels above the upper 95 %CI in both the
control and the post-TX margins. CCL1and CCL15 have
strong proinflammatory properties [27]. These results
are supportive of the reported evidence of increased
Th1 in patients with atherosclerosis [28] and in dialysis
patients [27]. This work defines the elevated proinflam-
matory chemokines in stable dialysis CKD stage 5
patients and highlights the importance of CCL1 and 15
as central in this process.
In the same pre-TX group, the proinflammatory CCL2,
3, and 5, and the homeostatic CCL21 levels was lower
than both control and post-TX patients. Again, CCL3 and
21 districted themselves as the two chemokines that were
preferentially and characteristically diminished in more
than 75 % of pre-TX patients below the control and
post-TX 95 %CI lower limit. CCL3 is important for T
cell and monocyte trafficking [29] and a key function of
CCL21 is in T cell and DC homing to lymph nodes
[30], which explains in part the role of deficient chemo-
kines in the immune deficiency state of CKD stage 5.
The profile of chemokine levels post-transplantation
requires several comments. First, CXCL5 and 12 had
normal levels. CCL15, 26, 27 and CXCL13 were signifi-
cantly elevated above control levels. Exceedingly high
chemokine levels that were preferentially characteristic
of post-TX were CCL26 and CXCL13. CCL26 has proin-
flammatory properties and plays an important role in
Th2 responses [31]. CXCL13 has a homeostatic function
and a key role in T and B cell trafficking in lymph nodes
[32]. In contrast, CCL4 and 5 were the preferentially
characterized post-TX chemokines that exceeded the
lower 95 %CI margins of both the control and pre-TX
patients. CCL4 is key in T/DC interaction [33], while
CCL5 is key for innate and adaptive immunity [34]. Cal-
cineurin inhibitor therapy used to suppress the immune
system is associated with a bias toward Th2/Th1 at least
in liver transplant recipients [20].
Further discussion on some of the similarities in chemo-
kine levels pre- and post-TX shows interesting findings.
First, CXCL12 had normal level in both groups. Secondly,
both patient groups had diminished levels of CCL 2, 3,
and 5. CCL2 key function is innate immunity and Th2
responses. CCL5 key function includes innate immunity
and adoptive immunity [34].
Preferentially increased pre-TX CCL levels included
CCL1 and 15, while preferentially diminished pre-TX
CCL levels were CCL3 and 21. Pre-TX CCL15 was
elevated above control to the extent that more than
90 % of patients in either patient’s group achieved level
above the upper 95 % CI. Further, pre-TX CL15 was so
exceedingly high to the extent that 93 % of pre-TX had
levels above the 95 % CI post-TX target. As such we
qualified CCL15 as preferentially characteristic of pa-
tients before TX. The significantly elevated CCL15 level
confirms its role in tissue injury in patients on dialysis
and patients with impaired native kidney function [21].
CCL15 is a potent angiogenic factor [35] that contributes
to chronic inflammation and fibrosis [36]. It is elevated in
patients with progressive CKD [37]. Elevated CCL15 may
target the native kidney as a source of inflammatory reser-
voir and also aggravate graft dysfunction. A striking recent
report describes how cleavage of CCL15, but not other
CCL family members, leads to more active form [38].
Elevated CCL15 may aggravate graft dysfunction. The
results raise its potential as a therapeutic target before
and after transplantation. CCL1 has a proinflammatory
function and supports Th2 responses [39]. In contrast to
CCL15, a mirror image finding is CCL3. It distinguishes
itself as the only diminished chemokine in both patient’s
groups and which more than 75 % of pre and post-TX
patients had levels below the lower set control margin.
In addition it’s pre-TX level was too low that 79.5 % of
post-TX patients have levels exceeding the upper pre-
TX cut off. Thus diminished CCL3 was qualified as char-
acteristic of pre-TX. It binds to CCR1 and 3. CCL3 has a
proinflammatory function and plays a role in T cell traf-
ficking [8, 30]. Key function of CCL3 is innate immunity
and T-cell and monocyte trafficking [29]. Decreased
level of CCL21 was also preferentially characteristic of
pre-TX. CCL21 key function is T cell and DC homing to
lymph nodes [30].
Preferentially elevated post-TX CCLs included CCL26
and CXCL13 while CCL4 and 5 had preferentially di-
minished levels. CCL26 supports Th2 responses and
CXCL13 is important for T and B cell trafficking. CCL26
was unique in that its level was significantly diminished
before TX and saw a significant elevation in a large
number of patients after transplant to the extent that in
all post-TX patients, CCL26 was uniquely elevated above
the upper pre-TX level. This central finding suggests
that there may be a biological relevance to this molecule
in transplant immunobiology [40, 41]. Interestingly, this
chemokine uses-receptor that is present on eosinophils,
basophils, T helper 2, monocytes, dentritic cells, plasma
cells and natural killer cells.
Transplantation seems to normalize some higher che-
mokine levels in CKD stage 5 which included in this
work CCL8, 11, 13, and CXCL10. These are predomin-
antly inflammatory chemokines [11]. Of interest, trans-
plantation seemed to even suppress previously elevated
chemokines in the hemodialysis patients. For example,
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CCL1 was significantly elevated before transplantation
and almost 90 % of pre-TX patients had higher level above
the control compared to only 11 % after transplantation.
CCL1 levels dropped below the lower control set limit in
more than half the TX patients. CCL4, and 24 had a simi-
lar fate. In contrast, transplantation did not seem to im-
prove diminished levels of certain chemokines like CCL3,
which is important for T cell and monocyte trafficking
[29], and CCL5, which is important in innate and adoptive
immunity [34].
The mean percentiles of pre-TX patients with chemo-
kine levels exceeding control levels (23.9 %) were almost
doubled compared to after transplantation (11.4 %).
Conversely the mean percentiles of pre-TX patients with
diminished CCL levels below the lower control was 13 %
before transplant and increased to 35.5 % after transplant-
ation, confirming the relatively diminished inflammatory
burden after transplant. There was also a noticeable shift
in chemokine profile that favors Th1 responses to Th2
responses after transplantation.
A major impetus for studying the chemokine system is
the possibility of using a chemokine blockade to treat in-
flammation induced tissue injury as seen in CKD and
even after transplantation and therefore, we believe that
this work has clinical relevance. Uremic toxins can
prime peripheral polymorphonuclear leukocyte as a key
mediator of low grade inflammation [42]. In fact persistent
inflammation has been suggested as a catalyst for other
risk factors in chronic kidney disease [43]. CVD is the
leading cause of morbidity in dialysis patients and after
organ transplantation. CCL15 is a chemokine that exerts
its biological activities through CCR1 and CCR3. A link
between increased its plasma levels and vascular injury
and progressive CKD has been suggested by several
researchers based on the strong association between in-
creased chemokine levels and progressive renal disease
[44, 45]. There are clinical and preclinical studies using
chemokine agonists and antagonists in patients with CKD
[46, 47]. For example, CCL15 binds to CCR1. Blocking
CCR1 with specific small molecule antagonists was shown
to retard progression in various types of rodent CKD
models [48]. As such we identify CCL15 as a target before
and after transplantation. We also identified CCL26 as a
potential target after transplant. In addition we identified
a possible target for agonistic activity to improve im-
munity in the kidney patient such as CCL3, 4 and 5.
There are obvious limitations to this work, in addition
to its retrospective nature and small number of patients.
We note that the cross-sectional study design does not
permit evaluating the association of biomarkers to inci-
dent of disease risk. We did not have kidney biopsies to
correlate changes in chemokines with tissue pathology.
We do not have a longitudinal follow up study of possible
natural variation in circulating chemokine levels and did
not have other groups of patients with renal failure in-
duced tissue injury like cardiovascular diseases to prove
causality between events and chemokine levels. The time
between transplant study time and transplant dates are
varied among patients. The number of controls was lower
than those of transplanted subjects, moreover patients
and controls were not sex matched (60 % of male in con-
trol group and about 50 % in the patients). Furthermore,
there was some missing data due to insufficient blood
samples on these individuals. In addition, measurements
of these inflammatory markers in the same patient before
and after transplantation should remain meaningful within
the context of this study design. We plan further studies
to address these clinically relevant questions.
Conclusions
To conclude, the goal of this study was to identify circu-
lating inflammatory chemokines of significance before and
after transplantation in a stable RTR population. The re-
sults identified chemokines that preferentially character-
ized pre-TX, including CCL1, and 15 which exceeded the
upper control and post-TX margins and CCL3 and 21
which exceeded the lower margin. After transplantation,
CCL26 and CXCL13 exceeded the control and pre-TX
margins, while CCL4 and 5 exceeded the lower set mar-
gins. Elevated circulating CCL 26 and CXCL13 seem to
strongly associate with transplantation and are possible
therapeutic targets to improve the post-TX course.
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